A clinical trial on Supplemental Nicotinamide to reduce severity of symptoms of schizophrenia

Supplemental Nicotinamide In the Treatment of Schizophrenia (SNITS): A clinical trial to reduce severity of symptoms of schizophrenia - SNITS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/04/032694

Enrollment

108

Registered

2021-04-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F200- Paranoid schizophrenia

Interventions

Intervention1: Nicotinamide supplementation arm: 54 participants will be given 1.5g of nicotinamide, daily for 26 weeks. Control Intervention1: Placebo arm: 54 participants will be given placebo sampl

Eligibility

Inclusion criteria

Inclusion criteria: (1) a diagnosis of SZ or schizoaffective disorder (2) no change in their anti-psychotic medication over the last 4 weeks (3) have the capacity to consent to the study and comply with study procedures.

Exclusion criteria

Exclusion criteria: (1) having a known or suspected active systemic medical disorder (2) currently pregnant or breastfeeding (3) currently enrolled in any other medical trial (4) currently taking any niacin supplement or daily multivitamin.

Design outcomes

Primary

Measure	Time frame
change in total PANSS score by adding scores for positive, negative and general psychopathologyTimepoint: baseline and 26 weeks	—

Secondary

Measure	Time frame
quality of lifeTimepoint: baseline and 26weeks	—

Countries

India

Contacts

Public ContactThara R

Schizophrenia Research Foundation

vijayaraghavan@scarfindia.org09043705687

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026